Copyright
©The Author(s) 2024.
World J Gastrointest Surg. Jan 27, 2024; 16(1): 95-102
Published online Jan 27, 2024. doi: 10.4240/wjgs.v16.i1.95
Published online Jan 27, 2024. doi: 10.4240/wjgs.v16.i1.95
Characteristic | No neoadjuvant chemotherapy (n = 400) | Neoadjuvant chemotherapy (n = 52) | P value |
Sex | 0.72 | ||
Female | 267 (59.1) | 36 (8.0) | |
Male | 133 (29.4) | 16 (3.5) | |
Race | 0.70 | ||
White | 241 (53.3) | 35 (7.7) | |
Black or African American | 38 (8.4) | 4 (0.9) | |
Asian | 30 (6.6) | 5 (1.1) | |
Other | 2 (0.5) | 0 (0) | |
Unknown/Not reported | 89 (19.7) | 8 (1.8) | |
Ethnicity | 0.19 | ||
Not Hispanic | 293 (64.8) | 41 (9.1) | |
Hispanic | 39 (8.6) | 7 (1.6) | |
Unknown/not reported | 68 (15.0) | 4 (0.9) | |
Diabetes | 93 (20.6) | 8 (1.8) | 0.20 |
History of smoking | 43 (9.5) | 3 (0.7) | 0.26 |
Dyspnea | 19 (4.2) | 2 (0.4) | 1.00 |
History of chronic obstructive pulmonary disease | 19(4.2) | 2 (0.4) | 1.00 |
History of congestive heart failure | 3 (0.7) | 0 (0.0) | 1.00 |
Hypertension requiring medication | 238 (52.7) | 24 (5.3) | 0.07 |
Steroid use for chronic condition | 9 (2.0) | 2 (0.4) | 0.37 |
> 10% loss body weight in last 6 mo | 19 (4.2) | 5 (1.1) | 0.18 |
Biliary stent (Yes) | 46 (10.3) | 6 (1.3) | 0.97 |
T (tumor) stage | 0.91 | ||
T0 & T1 | 43 (9.5) | 6 (1.3) | |
T2 | 140 (31.0) | 17 (3.8) | |
T3 & T4 | 136 (30.1) | 21 (4.7) | |
Tx & Unknown | 68 (15.0) | 7 (1.5) | |
N/A | 13 (2.9) | 1 (0.2) | |
N (node) stage | 0.24 | ||
N0 | 147 (32.5) | 14 (3.1) | |
N1 & N2 | 122 (27.0) | 23 (5.1) | |
Nx & unknown | 115 (25.5) | 14 (3.1) | |
N/A | 16 (3.5) | 1 (0.2) | |
M (metastasis) stage | 0.61 | ||
M0/Mx | 224 (50.0) | 34 (7.5) | |
M1 | 21 (4.6) | 3 (0.7) | |
Unknown | 95 (21.0) | 9 (2.0) | |
N/A | 60 (13.3) | 6 (1.3) | |
Mean (SD) | Mean (SD) | ||
Age | 67.0 (10.6) | 64.6 (9.1) | 0.07 |
Pre-operative serum albumin | 3.9 (0.6) | 3.9 (0.5) | 0.65 |
Pre-operative total bilirubin | 0.8 (1.2) | 0.4 (0.2) | < 0.01 |
Pre-operative BUN | 15.0 (6.0) | 16.1 (6.8) | 0.33 |
Pre-operative serum creatinine | 0.9 (0.3) | 0.9 (0.3) | 0.45 |
Pre-operative INR | 1.0 (0.1) | 1.0 (0.1) | 0.66 |
- Citation: Kim M, Stroever S, Aploks K, Ostapenko A, Dong XD, Seshadri R. Post-operative morbidity after neoadjuvant chemotherapy and resection for gallbladder cancer: A national surgical quality improvement program analysis. World J Gastrointest Surg 2024; 16(1): 95-102
- URL: https://www.wjgnet.com/1948-9366/full/v16/i1/95.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v16.i1.95